Home » Archive by Category

Syndication

Project Analyst / Research Associate at Simply Biotech (San Diego, CA)

October 30, 2014 – 9:01 am | Edit Post

PROJECT ANALYST / RESEARCH ASSOCIATE Simply Biotech specializes in recruiting exclusively for San Diego’s biotech commun … / Research Associate for a leading and growing San Diego biotech firm. The Project Analyst is responsible for…

Irvine Pharmaceutical Services Announces the Opening of an Analytical Facility in Hangzhou, China

October 30, 2014 – 8:25 am | Edit Post

IRVINE, Calif., Oct. 30, 2014 /PRNewswire/ – Irvine Pharmaceutical Services, Inc., a leading provider in cGMP contract development and parenteral manufacturing services, announces plans to open a new facility in Hangzhou, China. This 115,000sqft. newly built, state-of-the-art facility will expand Irvine’s service offerings into the Asian markets.

Irvine’s newest facility is scheduled to be fully operational in the first quarter of 2015. CEO and Founder, Dr. Assad J. Kazeminy explains, “Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support.”

Learn more about Irvine’s expansion into the Asian market – Visit us at booth 3110 at the 2014 AAPS Annual Meeting and Exposition in San Diego, CA on November 2 – 6, 2014.

About Irvine

Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine provides cGMP contract development and manufacturing services such as parenteral manufacturing (liquid and lyophilized), preformulation/formulation development, analytical development, biopharmaceutical development, stability storage, analytical chemistry, structural chemistry, microbiology, and drug delivery device testing.

Learn more at www.irvinepharma.com or call (949) 951-4425.
SOURCE Irvine Pharmaceutical Services, Inc.

Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals’ Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer

October 30, 2014 – 6:41 am | Edit Post

Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals’ Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer

York Hall Science Labs Get $6.5 Million Makeover to Help Students Graduate in Four Years

October 30, 2014 – 6:00 am | Edit Post

Four undergraduate teaching laboratories for biology and chemistry students have undergone a $6.5 million makeover as part of implementation of the UC San Diego Strategic Plan. The renovated labs in York Hall will eliminate a key barrier to students accessing impacted laboratory science courses—making it easier for them to graduate in four years.

California Brain Research Program Launched

October 30, 2014 – 6:00 am | Edit Post

Cal-BRAIN—a statewide research grants program that aims to revolutionize our understanding of the brain—is officially underway. The first call for proposals has gone out, and the program expects to announce its first awards in early 2015.

The Coming of Age of Stem Cell Therapy

October 30, 2014 – 6:00 am | Edit Post

In 2004, the therapeutic potential of stem cells persuaded more than 7 million Californians to approve Proposition 71, which allocated a whopping $3 billion for research and development of stem cell-based drugs and therapies that might someday address a medical dictionary’s worth of diseases and conditions.

Fate Therapeutics To Present At Nomura Biotechnology Conference

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will…

Immunomedics, Inc. Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc., (Nasdaq:IMMU) today announced that isactuzumab govitecan (IMMU-132), the Company’s proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce encouraging results in a Phase 2 clinical trial in heavily…

GreatCall Adds AliveCor Heart Monitor To Mobile Health Portfolio

October 30, 2014 – 5:00 am | Edit Post

Connection to Touch3 smartphone brings mobile heart health tracking directly to patients and their physicians SAN DIEGO October 30, 2014 GreatCall, Inc., the leader in creating mobile health and safety solutions for active aging, is bringing the ability to affordably track heart health anywhere, anytime to its Touch3 smartphone as a pilot program. The AliveCor Heart Monitor…

Neurocrine Biosciences, Inc. Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation…